Emergent BioSolutions, Inc. (EBS)
6.38
-0.80
(-11.14%)
USD |
NYSE |
Oct 16, 16:00
6.375
0.00 (0.00%)
After-Hours: 20:00
Emergent BioSolutions Cash from Operations (Quarterly) : 56.10M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 56.10M |
| March 31, 2026 | -33.80M |
| December 31, 2025 | 77.70M |
| September 30, 2025 | -2.30M |
| June 30, 2025 | 106.40M |
| March 31, 2025 | -11.20M |
| December 31, 2024 | -79.90M |
| September 30, 2024 | 153.70M |
| June 30, 2024 | 47.50M |
| March 31, 2024 | -62.60M |
| December 31, 2023 | 32.10M |
| September 30, 2023 | 60.00M |
| June 30, 2023 | -114.40M |
| March 31, 2023 | -184.00M |
| December 31, 2022 | 92.80M |
| September 30, 2022 | -74.00M |
| June 30, 2022 | -15.60M |
| March 31, 2022 | -37.30M |
| December 31, 2021 | 328.10M |
| September 30, 2021 | 16.70M |
| June 30, 2021 | -29.70M |
| March 31, 2021 | 5.10M |
| December 31, 2020 | 245.10M |
| September 30, 2020 | 105.20M |
| June 30, 2020 | 127.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 57.80M |
| December 31, 2019 | 122.10M |
| September 30, 2019 | -3.10M |
| June 30, 2019 | -35.80M |
| March 31, 2019 | 104.80M |
| December 31, 2018 | -165.76M |
| September 30, 2018 | 173.97M |
| June 30, 2018 | 34.58M |
| March 31, 2018 | -0.991M |
| December 31, 2017 | 78.95M |
| September 30, 2017 | 33.52M |
| June 30, 2017 | 54.00M |
| March 31, 2017 | 41.67M |
| December 31, 2016 | -9.174M |
| September 30, 2016 | 1.602M |
| June 30, 2016 | 18.89M |
| March 31, 2016 | 42.17M |
| December 31, 2015 | 3.07M |
| September 30, 2015 | 104.76M |
| June 30, 2015 | 2.503M |
| March 31, 2015 | -65.87M |
| December 31, 2014 | 51.82M |
| September 30, 2014 | 78.92M |
| June 30, 2014 | 10.82M |
| March 31, 2014 | -29.24M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Exelixis, Inc. | 307.74M |
| Arcturus Therapeutics Holdings, Inc. | -20.92M |
| Capricor Therapeutics, Inc. | -31.49M |
| ADMA Biologics, Inc. | 29.54M |
| Akebia Therapeutics, Inc. | 3.525M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -52.30M |
| Cash from Financing (Quarterly) | -24.40M |
| Free Cash Flow | 85.90M |
| Free Cash Flow Per Share (Quarterly) | 1.046 |
| Free Cash Flow to Equity (Quarterly) | 100.80M |
| Free Cash Flow to Firm (Quarterly) | 64.84M |
| Free Cash Flow Yield | 24.82% |